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Summary
Objective: The purpose of this study was to identify genes that are differentially expressed in normal versus osteoarthritic human articular
cartilage as either potential novel therapeutic targets or diagnostic markers of this disease.
Design: mRNA was isolated from histologically normal and osteoarthritic adult human articular cartilage. The Differential Display technique
was employed which identified differentially expressed genes in the normal and diseased tissue. Northern and reverse Northern hybridization
were used to confirm the gene expression pattern. Immunohistochemistry and in-situ hybridization were used to localize expression of Egr-1
protein and mRNA respectively in cartilage.
Results: A transcription factor, early growth response protein-1 (Egr-1) was found to be down-regulated more than six-fold in multiple human
OA cartilage samples when compared to normal tissue. Immunohistochemistry indicated that Egr-1 was expressed throughout normal adult
cartilage, in deep-, mid- and superficial-zones. In contrast, in OA cartilage there was expression of Egr-1 mRNA and protein only in the
chondrocytes undergoing cloning.
Conclusions: Egr-1 is differentially expressed in OA versus normal cartilage and because of its role in transcriptional activation and
repression and regulation of proliferation, differentiation and apoptosis, Egr-1 may play an important role in the pathogenesis of OA.
Up-regulation of Egr-1 may therefore provide a novel therapeutic approach for either the prevention or treatment of OA. © 2000
OsteoArthritis Research Society International
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Osteoarthritis (OA) is a widespread and debilitating degen-
erative joint disease for which there are currently no
disease-modifying therapies. OA is characterized by pro-
gressive articular cartilage destruction, secondary inflam-
mation of the synovial membrane as well as thickening of
subchondral bone.1,2 Aging, mechanical impact loading
and reactive oxygen molecules such as nitric oxide are
important factors contributing to the pathogenesis of
OA.3–5 The pathogenesis of OA may also result from the
inappropriate response of chondrocytes to catabolic and
anabolic stimuli from mitogens i.e. growth factors and
hormones. These factors regulate chondrocyte develop-
ment and therefore maintain cartilage homeostasis.6,7
Transcription factors and immediate early genes are the
earliest downstream nuclear targets of mitogens. They play
key roles in regulating gene expression, often initiating
pathways of gene activation and repression that are critical
for cell function.8,9 Dysregulation of immediate early161gene expression can have severe cellular and, therefore,
physiological consequences.10
Chondrogenesis and cartilage homeostasis in the
growth plate are complex processes involving proliferation,
differentiation and apoptosis.11,12 There are numerous
reports of transgenic mouse models which have resulted in
skeletal abnormalities because of dysregulated chondro-
cyte maturation resulting from either knockout or over-
expression of genes that are critical for development and
maintenance of the skeleton.13–15
The factors responsible for the altered properties of
chondrocytes in OA have not been well defined.16 How-
ever, chondrocytes derived from OA cartilage maintain their
phenotype in culture,17,18 suggesting that there are geno-
type changes in these cells which may contribute to their
altered properties. The identification and characterization of
OA-related genes may be important in understanding the
pathogenesis of OA and discovering novel pharmaceutical
targets for treatment and/or prevention of the disease. In
this study, we have employed the technique of Differential
Display19 to search for genes differentially expressed in
normal versus osteoarthritic (OA) adult human cartilage.
Here we report the identification of early growth response
protein-1 (Egr-1) as a differentially expressed gene in
multiple cartilage tissue samples from OA patients com-
pared to normal cartilage. Understanding the regulation
of Egr-1 gene expression during the pathogenesis of
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debilitating and extensive disease.Materials and methods
TISSUE PROCUREMENT AND PROCESSING
Human osteoarthritic cartilage was obtained from knee
and hip replacement surgeries with informed consent.
Normal human cartilage was obtained at the time of
autopsy through the Anatomic Gift Foundation (Laurel,
MD) and the National Disease Research Interchange
(Philadelphia, PA). Three normal and three osteoarthritic
samples were used for the Differential Display. Six normal
and six osteoarthritic samples were used to confirm the
Differential Display by Northern blot and reverse Northern
blot analysis. Three normal and four osteoarthritic
cartilage samples were used for in-situ hybridization,
and one normal and one osteoarthritic sample for
immunohistochemistry (described below).
For immunohistochemical and in-situ hybridization
analyses the tissue was dipped briefly into a 5% solution
(w/v) of polyvinyl alcohol (PVA) and then chilled (−70°C) by
precipitate immersion in cooled n-hexane (low in aromatic
hydrocarbons grade, boiling range 67–70°C). Cryostat sec-
tions (8 m) of unfixed, undecalcified cartilage were cut on
a modified Hacker cryostat equipped with a finely polished
tungsten-tipped steel knife. The temperature of the cryostat
cabinet was kept below −25°C. The sections were picked
off onto glass slides which, for immunohistochemistry and
in-situ hybridization studies, had been coated with
3-aminopropyltriethoxy saline. For RNA preparations, fresh
cartilage tissue was frozen immediately in liquid nitrogen
and stored at −80°C prior to extraction.EXTRACTION AND PURIFICATION OF CARTILAGE TOTAL RNA
Total RNA was extracted from cartilage by a modified
method of Adams et al.20 All reagents were nuclease-free.
Frozen cartilage (0.5–1.0 g) was powdered in a Spex
Freezer Mill (SPEX, Metuchen, NJ) and immediately hom-
ogenized in 4 ml of 4 M guanidinium isothiocyanate
solution (GibcoBRL, Gaithersburg, MD) with 2.5 l of
2-mercaptoethanol. The extracts were centrifuged at
1500 g for 10 min at 4°C and the supernatant was trans-
ferred to a separate tube. The extraction of the pellet was
repeated and the supernatants were pooled. Triton X-100
(0.65 ml of 25%) was added to the supernatants which
were mixed and incubated on ice for 15 min. Sodium
acetate (8.0 ml of 3 M at pH 6.0) was added, mixed and
incubated on ice for 15 min. The supernatants were
extracted with 12 ml phenol (DEPC-water saturated) and
3 ml chloroform/isoamyl alcohol (49:1), mixed and incu-
bated on ice for 10 min, then centrifuged at 15,000 g for
20 min. The extraction and separation of the aqueous
phase was repeated twice with 10 ml phenol and 10 ml
chloroform/isoamyl alcohol (49:1). The RNA in the aqueous
phase was precipitated with 0.8 volumes of isopropanol on
ice for 5 min followed by centrifugation at 15,000 g for
30 min. The pellet was dissolved in 0.9 ml of lysis buffer
RLT (Qiagen RNeasy kit, Qiagen, Chatsworth, CA) then
0.9 ml of 70% ethanol was added and mixed by inversion.
The solution was applied to an RNeasy Spin column by
centrifugation at 8000 g for 25 sec. The column was
washed with 0.7 ml of wash buffer RW1 and centrifuged at
8000 g for 25 sec. The column was placed into a newcollection tube and washed with buffer RPE (0.5 ml) and
centrifuged at 8000 g for 25 sec. The final wash was with
0.5 ml of buffer RPE with centrifugation at 14,000 rpm for
2 min. The column was transferred to a new collection tube
and the RNA was eluted with 50 l of nuclease-free water
followed by centrifugation at 8000 g for 1 min. RNA was
quantitated by spectrophotometric analysis and structural
integrity was confirmed by electrophoresis.DIFFERENTIAL DISPLAY (DD)
RNA DD was performed using one-base anchored
oligodeoxythymidylate primer HT11C (5′-AAGCTTTTTTTT
TTTC-3′) to reverse-transcribed mRNA to first-strand
cDNA, which was amplified subsequently by the polym-
erase chain reaction (PCR) using the arbitrary up-stream
primer HAP46 (5′-AAGCTTCGGTCCT-3′) (GenHunter,
Nashville,TN). The normal control individuals from which
RNA was extracted were all males aged 75, 79 and 63
years. The patient biopsy information is abbreviated as
follows: age/sex/grade of OA tissue. The OA was graded as
early OA (EOA) and advanced OA(AOA). The three patient
samples were: 75/M/EOA, 73/M/EOA and 93/M/AOA. PCR
conditions used were the same as described previously.21
PCR products were analyzed on a 6% DNA sequencing gel
using 0.5 mM[-35S]-labeled dATP (1200 Ci/mmol). The
bands on the cDNA ladder that were differentially
expressed in normal versus OA lanes were cut out of the
gel, eluted, and reamplified by PCR.CLONING AND SEQUENCING
The reamplified DD band was subcloned into pCR2.1
plasmid vector using the TA cloning kit (Invitrogen, San
Diego, CA). Individual clones were sequenced using
an automated DNA sequencer (Applied Biosystems Inc.
Foster City, CA). The 342 bp cDNA of Egr-1 sequence
(nucleotides 2806 to 3147; GenBank: X52541) was used
as a probe for the Northern blot, reverse Northern blot and
in-situ hybridization.NORTHERN BLOT AND REVERSE NORTHERN BLOT ANALYSIS
Total RNA from cartilage tissues of different individuals
was isolated as described above.20 RNA’s for Northern
hybridization were RNA pools from different individuals.
The normal control individuals from which pooled RNA
were extracted was a 31-year-old male and 44-year-old
female. The three patient samples were: 75/M/EOA, 63/M/
EOA and 93/M/AOA. RNA was separated on 1.1% agarose
and 0.86 M formaldehyde gel and then transferred to a
nylon filter (Micron Separations, Westboro, MA). The probe
from reamplified 342 bp cDNA was labeled with 32P using
a random-prime labeling kit (Boehringer Mannheim,
Indianapolis, IN). The filters were hybridized for 1 h at 68°C
using ExpressHyb hybridization solution (Clontech Lab,
Paolo Alto, CA). A probe for the -actin gene (X00351)
(Clontech Lab. Paolo Alto, CA) was used to correct for
lane loading differences on the Northern blots. Bands
were quantitated using a 355 personal densitometer SI
(Molecular Dynamics, Sunnyvale, CA).
Reverse Northern blot analysis was performed by im-
mobilization of 30 ng of the cloned 342 bp cDNA of Egr-1
on a nylon filter (Micron Separations, Westboro, MA). The
normal control individuals from which pooled RNA were
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respectively. The patients biopsy information was: 75/M/
EOA, 71/M/EOA and 73/M/EOA. After blotting, the cDNA
was denatured and neutralized by incubation of the mem-
brane in 0.5 M NaOH/1.5 M NaCl for 3 min and in 0.5 M
Tris-HCl, pH 7.2/1.5 M NaCl/1 mM EDTA for 3 min, respec-
tively. 30 g of total RNA from normal and OA RNA pools
were reverse transcribed as described above, except 1 g
of OligodT15 was used as a primer and 5 l [a-32P] dCTP(3000 mCi/mmol) were included. The cartilage samples of
pooled RNA for the reverse Northern were different from
the regular Northern blot. Probes with equal amounts of
radioactivity (2×106 cpm/ml) were added to each filter and
hybridized. The hybridization conditions were the same as
that for Northern hybridization.IN-SITU HYBRIDIZATION
pBluescript SK containing cloned 342 bp Egr-1 cDNA
was linearized with XhoI, then transcribed from the T3
promoter to generate the sense strand (negative control) or
with XbaI, then transcribed from the T7 promoter to gener-
ate the antisense (positive) strand. Riboprobes were pre-
pared using the Promega (Madison, WI) in-vitro
transcription kit with 35S-thio CTP (Amersham, Arlington
Heights, IL). Following transcription, cDNA templates
were digested with RQ1 RNase-free DNase I (Promega,
Madison, WI), and unincorporated nucleotides were
removed by centrifugation through Quick Spin Sephadex
G-50 columns (Boehringer-Mannheim, Indianapolis, IN).
RNA transcripts with a specific activity in excess of
108 cpm/mg were used for hybridization. The normal tissue
was from a 52-year-old male individual and advanced OA
tissue from a 58-year-old female patient.
In-situ hybridization was performed by the original
method of Zeller and Rogers23 with modifications detailed
by,22 as follows. Cryosections were fixed in 4% paraformal-
dehyde, washed, dehydrated and frozen at −20°C. Prior to
hybridization, sections were hydrated, demineralized and
acetylated. Hybridization was carried out at 42°C for 4 h
and post-hybridization washes were to a final stringency of
0.1×SSC (20×SSC: 3 M NaCl, 0.3 M Na citrate, pH 7.0).
Sections were dehydrated, air dried and coated inAmersham LM-1 emulsion. Following exposure at 4°C for
2 weeks, the slides were developed in Kodak developer
and counterstained with methylene blue.Fig. 1. Identification by differential display (DD) of gene expression
in normal (N1, N2 and N3) and early osteoarthritic (EOA), and
advanced osteoarthritic (AOA) tissue. Information of age/sex/
sample on the individuals was 75/M/N1, 79/M/N2, 63/M/N3, 75/M/
EOA1, 73/M/EOA2, and 93/M/AOA. DD was performed using
a 5′ arbitrary primer HAP46 (5′-AAGCTTCGGTCCT-3′) and a
3′ HT11C (5′-AAGCTTTTTTTTTTTC-3′) anchored primer and
resolved by 6% DNA sequencing gel. The Egr-1 band is labeled.Results
Total RNA was isolated from both normal and OA carti-
lage tissue from multiple individuals. RNA was reverse-
transcribed, and PCR was performed in the presence of
-[35S] dATP. The PCR fragments were separated on 6%
DNA sequencing gels and autoradiographed. Each DD
lane yielded 100–130 discrete bands. The patterns of
amplified PCR products from six independent samples of
RNA’s from normal or OA cartilage showed virtually identi-
cal banding patterns (Fig. 1). A band amplified by primer
pair HT11C and HAP46 was identified that was expressed
strongly in three normal tissue lanes, but only weakly
expressed in three OA samples (Fig. 1). The cDNA was
removed from the sequencing gel, PCR reamplified using
the same primer pair used in the DD reaction, and used to
probe a Northern blot containing RNA’s from two normal
and three diseased cartilage samples (Fig. 2A). The cDNA
hybridized to a RNA transcript of 3.7 kb (Fig. 2A). Quanti-
tatively, there was a six to seven-fold lower expression of
the transcript in OA cartilage compared to that found in
normal cartilage. Reverse Northern blotting containing
RNA’s from four normal and three diseased cartilage
samples also confirmed the DD band pattern (Fig. 2B).
After sequencing, the DD-derived cDNA was identified
as human early growth response-1 (Egr-1) gene by a
GenBank BLAST search (X52541) (Fig. 3). The nucleo-
tides of this cDNA matched nucleotides 2806–3147 of
Egr-1. As expected, the band was also found to contain the
sequence of the amplification primers at 5′ and 3′ ends. In
the amplification primers, there were three positions whereIMMUNOHISTOCHEMISTRY
Immunohistochemistry was performed on human carti-
lage cryostat sections (6 m) processed as described pre-
viously.22 The normal tissue was from a 25-year-old female
individual and advanced OA tissue from a 87-year-old
female patient. Normal and osteoarthritic human cartilage
tissues were fixed with acetone for 2 min and sections were
incubated with primary rabbit polyclonal antibody (4 g/ml)
directed toward Egr-1 (Santa Cruz Biotechnology, Santa
Cruz, CA) for 30 min. The binding of the primary antibody
was visualized using the LSAB alkaline-phosphatase kit
and new fuchsin substrate/chromagen system, according
to the manufacturer’s protocols (DAKO, Carpinteria, CA).
All incubations were performed at room temperature, and
antibody was diluted with 0.05 M Tris-HCl buffer, pH 7.5.
After each incubation, the sections were washed three
times with Tris-HCl buffer. As a negative control, sections
were incubated with Egr-1 blocking peptide (20 g/ml)
(Santa Cruz Biotechnology, Santa Cruz, CA) before
incubation with anti-Egr-1 antibody.
164 F.-L. Wang et al.: Egr-1 is down-regulated in osteoarthritic cartilageFig. 2. Northern blot (A) and reverse Northern blot (B) analysis of
differential expression of Egr-1 in normal versus osteoarthritic
human cartilage. For Northern hybridization, 20 g of total RNA
from normal (N) and osteoarthritis (OA) cartilage tissue was loaded
onto the gel and the blot was probed with the cDNA from Egr-1 as
described in the Materials and methods. The same blot was
re-probed with -actin to correct for lane loading differences.
-actin indicates equal loading in N and OA lanes. Densitometry
indicates an approximate 6 to 7-fold decrease in expression of
Egr-1 in RNA from OA compared to normal tissue. Reverse
Northern blot using 20 ng cloned cDNA from DD band was probed
by [32P]dCTP-labeled first strand cDNA (2×106 cpm/ml). The
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA was
used as loading control.Fig. 3. Nucleotide sequence comparison between human Egr-1 (X52541) and the cDNA identified by DD. The sequences of primers for the
DD and consensus polyadenylation signal (AATAAA) are underlined. Start (ATG) and stop (TAA) codons of human Egr-1 are denoted by bold
letters and double underlines. Boxes denote the nucleotides of DD cDNA mismatching human Egr-1.the DD cDNA nucleotides mismatched human Egr-1
nucleotides. The mismatched nucleotides are denoted by
boxes (Fig. 3).
Expression of Egr-1 protein by immunohistochemistry in
normal, superficial, mid and deep zone cartilage24 wascompared with advanced OA cartilage25 (Fig. 4). In the OA
tissue, the structural features of the disease were evident.
The cartilage surface was fissured and disrupted by deep
clefts that enter the basal areas (Fig. 4D). In the superficial
and mid-zone, there was an decrease in chondrocyte
density, with associated clustering and cloning (Fig. 4D and
E). Temporal expression of Egr-1 protein was different in
normal versus osteoarthritic adult human cartilage tissue.
Egr-1 protein was present throughout the normal cartilage
from the superficial to deep zone (Fig. 4A, B and C). In
contrast, in OA tissue, only the cloning chondrocytes and
occasional individual chondrocytes in the mid-zone stained
positively for Egr-1. Egr-1 expression was absent from the
deep zone and from the superficial zone, which was eroded
and disrupted. The difference in staining intensity for Egr-1
between normal and OA tissue is observable with the
cloning chondrocytes expressing relatively high levels of
Egr-1 protein compared to chondrocytes in normal cartilage
(Fig. 4). Sections incubated with the Egr-1 blocking peptide
as a negative control show negative staining (Fig. 4G).
The expression of Egr-1 mRNA in cryostat sections of
aged matched normal and advanced OA cartilage was
analyzed by in-situ hybridization (Fig. 5). In normal carti-
lage, characterized by an intact superficial zone and pro-
teoglycan staining, Egr-1 mRNA expression was low to
undetectable (Fig. 5A). However, in advance osteoarthritic
tissue, characterized by fissuring, cloning of chondrocytes
and loss of proteoglycan staining, intense Egr-1 mRNA
expression was demonstrated in the cloning chondrocytes
(Fig. 5B and C). Individual chondrocytes of the mid-zone
Osteoarthritis and Cartilage Vol. 8 No. 3 165Fig. 4. Immunohistochemistry of Egr-1 in normal (A,B,and C) and advanced osteoarthritic (D,E, and F) human cartilage tissues. Surface and
superficial zones (A and D), mid-zone (B and E), and deep zone and subchondral bone tissue (C and F) of normal and osteoarthritic tissue.
Cartilage sections were stained with a polyclonal antibody directed toward Egr-1. Sections were incubated with rabbit anti-Egr-1 (4 g/ml)
followed by biotin-conjugated secondary antibody, then incubated with alkaline-phosphatase-conjugated streptavidin and visualized by New
Fuchsin substrate-chromogen solution (magnification, ×20). Sections incubated with the Egr-1 blocking peptide were used as negative
controls (Fig. 4G).
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Egr-1 mRNA expression in the cloning chondrocytes was
consistent with the protein expression. The low signal
found in the normal cartilage tissue by in-situ hybridization
could be due to the lack of sensitivity compared to
immunocytochemistry.
Collectively, the DD, Northern blot (regular and reverse),
immunohistochemistry and in-situ hybridization data sug-
gest that human Egr-1 is expressed in the chondrocytes of
adult human cartilage and that Egr-1 mRNA expression is
down-regulated during the development of OA. However,
rather than general expression found in normal cartilage,
there is focused and increased expression in the cloning
chondrocytes of the superficial zone and in the reparative
areas as a result of fissuring in OA cartilage.Fig. 5. In-situ hybridization of Egr-1 mRNA expression in normal and advanced osteoarthritic human cartilage. (A) A cryostat section of
normal human cartilage with an intact superficial zone and consistent proteoglycan staining from a 52-year-old was hybridized with the
antisense Egr-1 riboprobe. There was very low to undetectable hybridization signal for Egr-1 mRNA (magnification, ×10). (B) A cryostat
section of advanced osteoarthritic human cartilage with deep fissuring, chondrocyte cloning and loss of proteoglycan staining from a
58-year-old was hybridized with the antisense Egr-1 riboprobe. The expression of Egr-1 mRNA was intense in cloning chondrocytes (arrows)
of the superficial layer. Moderate levels of mRNA were also detected in individual chondrocytes (arrowheads) (magnification, ×20). (C)
Greater magnification of (B) demonstrating intense Egr-1 mRNA expression in cloning chondrocytes (magnification, ×40). (D) Serial section
of (B) hybridized with the sense strand control (magnification, ×10).Discussion
Early growth response-1 (Egr-1) mRNA was identified by
DD as a relatively strong band in normal cartilage tissue
that was significantly down-regulated in samples from
osteoarthritic cartilage. DD has been successfully em-
ployed previously to look for differentially expressed genes
in cartilage tissue.26–29 We have extended the initial pro-cedure of identification of genes by confirming differential
expression and cell-specific expression by immunocyto-
chemistry and in-situ hybridization. One of the major issues
with DD technology is the abundance of false positives.30
We confirmed the initial DD results by performing multiple
Northern blots, and confirming the consistent patient-to-
patient (total of 13 normal compared to 14 osteoarthritic
tissues when combining the results from the different tech-
niques) down-regulation of Egr-1 mRNA in diseased carti-
lage tissue. The number of total cells was higher in the
normal compared to OA cartilage and therefore this could
account for the increased total expression of Egr-1 in nor-
mal cartilage compared to disease tissue. It also appears
that in contrast to the general low expression in normal
cartilage Egr-1 could, in fact, be up-regulated in the cloning
chondrocytes as evidenced by the increased expression
indicated by immunocytochemistry and in-situ hybridiza-
tion.
Genes such as the cartilage intermediate layer protein
(CILP) are differentially expressed in aged cartilage.31
Based on our data in which the normal and OA tissue were
age matched in the DD and reverse Northern, we would
suggest that Egr-1 is regulated by disease state and not
age. In the DD, all normal samples were positive and OA
Osteoarthritis and Cartilage Vol. 8 No. 3 167samples negative regardless of the age of the individuals.
Specifically, in the DD we used normal tissue from the
femoral head and OA tissue of the femoral condyle from the
same individual and Egr-1 expression was found to be
down-regulated in the diseased tissue (Fig. 1). We there-
fore suggest that the differential expression of Egr-1 is due
to OA and not to aging or aging plus OA.
Egr-132,33 which has also been referred to as NGFI-A,34
Krox-2435 and zif/26836 is an immediate early gene, with
zinc-finger DNA-binding properties that acts as a nuclear
coupler of early cytoplasmic events to long-term alterations
in gene expression.32,36 The Egr-1 protein binds to a
specific GC-rich sequence in the promoter region of many
target genes to regulate their expression.37,38 Egr-1
expression is affected by numerous stimuli including
mitogens such as platelet derived grown factor (PDGF),
epidermal growth factor, fibroblast growth factor and bone
morphogenetic protein-4.39,40 During the differentiation
of rat calvarial preosteoblasts, Egr-1 was transiently
induced41 and has been functionally implicated in cell
proliferation, differentiation and apoptosis.32,39,42 In some
cells Egr-1 not only acts as a transcriptional activator, but
also as a repressor39,43 and has been shown in human
fibrosarcoma cells to negatively regulate tumor growth.44
Egr-1 has been shown to stimulate TGF- expression, a
member of a gene family involved in proliferation and
differentiation of cartilage chondrocytes.45 In particular,
TGF- has been suggested to control the transition of
chondrocytes from the proliferative to the hypertrophic
state.46 It appears, therefore, to have multiple tissue-
selective roles and is a good candidate for a gene involved
in normal cartilage homeostasis, whose dysregulation may
have severe physiological consequences.
In terms of its expression in the skeleton, Egr-1 has been
shown to be expressed during development in epiphyseal
cartilage and the articular surfaces of the developing limbs
and at the articular surfaces of joints and in the interstitial
cells.47 In particular, high expression has been measured in
several areas undergoing bone formation including the
periosteal regions of the developing long bones.47 How-
ever, there is no data available concerning the role of Egr-1
in normal adult chondrocytes or in diseased cartilage.
In rheumatoid arthritis (RA), Egr-1 has been previously
reported to be up-regulated in synoviocytes but not in
OA.48 This may reflect the acute inflammatory response
observed in RA, as Egr-1 has also been reported to be
induced by cytokines such as TNF-.49 Down-regulation of
Egr-1 as a consequence of development of OA is the first
report of modulation of this gene in adult human articular
cartilage.
Hallmarks of the pathogenesis of OA include a reduction
in chondrocyte cell number,50,51 an increase in the number
of degenerative chondrocytes (fragmented cells, lipid drop-
lets, nuclear clumping and loss of organelles),2 uncon-
trolled matrix degradation and articular cartilage swelling.
Cartilage matrix degradation results from cleavage by
chondrocyte-derived proteolytic enzymes. Several in-vitro
studies have indicated that factors which contribute to the
pathogenesis of the disease, including TNF,52,53 IL-1-
stimulated nitric oxide54 and Fas ligand,55 stimulate
chondrocyte apoptotic cell death. Indeed, TNF- has been
shown to directly stimulate Egr-1 expression.49 There is
considerable evidence suggesting the apoptosis of
chondrocytes in the growth plate during endochondral bone
formation56–58 and an increase in apoptosis from human
OA tissue samples.59,60 Therefore, there appears to be a
major role for apoptosis in normal chondrocyte develop-ment. In addition, failure of this essential process could
have severe skeletal consequences. Thus, because of its
proposed role in the control of apoptosis,61 it may be that
Egr-1 normally coordinates chondrocyte apoptosis during
skeletal maintenance. As a consequence of the initiation of
the disease process, Egr-1 down-regulation may result in
dysregulated apoptosis which ultimately contributes to
the pathogenesis of OA. It has been proposed that
apoptosis of chondrocytes during differentiation may serve
to control cell number and phenotype in a rapidly remod-
eling tissue.62 Removal of terminally differentiated
chondrocytes within the calcified cartilage matrix would
provide the microenvironment for vascular invasion,62
osteoclast and osteoblast differentiation and osteoid
synthesis and mineralization.56
It is not clear at this point whether Egr-1 down-regulation
is; (i) the controlling factor, (ii) one of a number of critical
factors, (iii) or is down-regulated as a consequence of the
disease process during the pathogenesis of OA. If it plays a
role in controlling the development of the disease then
Egr-1 itself, or up- and down-stream effectors of this gene,
may provide potential novel therapeutic targets in OA.
Alternatively, if Egr-1 is down-regulated as a result of the
disease process, it may at the very least have potential
diagnostic utility in OA. Mechanical stress, shear forces
and reactive oxygen molecules have been claimed to be
responsible for the induction of OA and these have been
shown to modify expression of immediate early genes. It is
therefore possible that one of these factors could be
affecting expression of Egr-1 which ultimately contributes to
the pathogenesis of OA.
Continued investigation of the potentially complex role of
Egr-1 in chondrocyte proliferation, differentiation and
apoptosis may provide insight into the underlying
biochemistry of normal cartilage turnover and possibly the
pathogenesis of OA, where normal cartilage homeostasis
is dysregulated.References
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